However, single-agent therapy with either anti–PD-1 or PD-L1 antibodies has failed to elicit meaningful responses in many tumor types — e.g., glioblastoma (3), pancreatic ductal adenocarcinoma (PDAC) (4, 5), and differentiated thyroid cancers (6). This evidence concerns the gene PDCD1 and thyroid gland carcinoma.